In vivo measurements of the fraction of dose of bleomycin labeled with cobalt 57 delivered to human tumors
Dov Front(Rambam Health Care Campus), Gerald M. Kolodny(Beth Israel Deaconess Medical Center), Galina Iosilevsky, Alex Frenkel(Girls Incorporated), Einat Even‐Sapir(Tel Aviv Sourasky Medical Center), Ron Epelbaum(University of Bern), Eliezer Robinson, David Milstein(Technion – Israel Institute of Technology), Ora Israel(Technion – Israel Institute of Technology)
Cited by 5
Related Papers
Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist
|Cell Metabolism|2015|1k
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
|Journal of Nuclear Medicine|2009|381
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
|Nutrition and Cancer|2010|279